Summary of COVID-19 ensovibep studies
Studies
Meta Analysis
Hide extended summaries
400 patient ensovibep early treatment RCT: 89% lower mortality (p=0.06), 78% fewer combined hospitalization/ER visits (p=0.02), 87% lower hospitalization (p=0.01), and 87% improvement (p=0.01).
RCT 407 mild to moderate COVID-19 outpatients showing faster viral clearance, lower risk of hospitalization/ER visits, and shorter time to sustained recovery with ensovibep treatment (75/225/600mg single infusion). There were 2 COVID-19 related deaths in the placebo group and none in the ensovibep groups.
May 2024, Open Forum Infectious Diseases, https://academic.oup.com/ofid/advance-article/doi/10.1093/ofid/ofae233/7664367, https://c19p.org/kingsley
RCT 485 hospitalized patients showing no significant differences with ensovibep treatment. Intravenous ensovibep, 600mg.
Aug 2022, Annals of Internal Medicine, https://www.acpjournals.org/doi/10.7326/M22-1503, https://c19p.org/barkauskas
400 patient ensovibep early treatment RCT: 89% lower mortality (p=0.06), 78% fewer combined hospitalization/ER visits (p=0.02), 87% lower hospitalization (p=0.01), and 87% improvement (p=0.01).
RCT 407 mild to moderate COVID-19 outpatients showing faster viral clearance, lower risk of hospitalization/ER visits, and shorter time to sustained recovery with ensovibep treatment (75/225/600mg single infusion). There were 2 COVID-19 related deaths in the placebo group and none in the ensovibep groups.
May 2024, Open Forum Infectious Diseases, https://academic.oup.com/ofid/advance-article/doi/10.1093/ofid/ofae233/7664367, https://c19p.org/kingsley
2. Barkauskas et al., Efficacy and Safety of Ensovibep for Adults Hospitalized With COVID-19
485 patient ensovibep late treatment RCT: 17% lower mortality (p=0.46), 6% improved recovery (p=0.55), and 7% higher hospital discharge (p=0.46).RCT 485 hospitalized patients showing no significant differences with ensovibep treatment. Intravenous ensovibep, 600mg.
Aug 2022, Annals of Internal Medicine, https://www.acpjournals.org/doi/10.7326/M22-1503, https://c19p.org/barkauskas
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.